Literature DB >> 20350531

Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.

Dominik Fuchs1, Volker Daniel, Mahmoud Sadeghi, Gerhard Opelz, Cord Naujokat.   

Abstract

Leukemia stem cells are known to exhibit multidrug resistance by expression of ATP-binding cassette (ABC) transporters which constitute transmembrane proteins capable of exporting a wide variety of chemotherapeutic drugs from the cytosol. We show here that human promyeloblastic leukemia KG-1a cells exposed to the histone deacetylase inhibitor phenylbutyrate resemble many characteristics of leukemia stem cells, including expression of functional ABC transporters such as P-glycoprotein, BCRP and MRP8. Consequently, KG-1a cells display resistance to the induction of apoptosis by various chemotherapeutic drugs. Resistance to apoptosis induction by chemotherapeutic drugs can be reversed by cyclosporine A, which effectively inhibits the activity of P-glycoprotein and BCRP, thus demonstrating ABC transporter-mediated drug resistance in KG-1a cells. However, KG-1a are highly sensitive to apoptosis induction by salinomycin, a polyether ionophore antibiotic that has recently been shown to kill human breast cancer stem cell-like cells and to induce apoptosis in human cancer cells displaying multiple mechanisms of drug and apoptosis resistance. Whereas KG-1a cells can be adapted to proliferate in the presence of apoptosis-inducing concentrations of bortezomib and doxorubicin, salinomycin does not permit long-term adaptation of the cells to apoptosis-inducing concentrations. Thus, salinomycin should be regarded as a novel and effective agent for the elimination of leukemia stem cells and other tumor cells exhibiting ABC transporter-mediated multidrug resistance. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350531     DOI: 10.1016/j.bbrc.2010.03.138

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  73 in total

1.  Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK.

Authors:  Bei Zhang; Xueya Wang; Fengfeng Cai; Weijie Chen; Uli Loesch; Johannes Bitzer; Xiao Yan Zhong
Journal:  Tumour Biol       Date:  2012-07-07

2.  Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.

Authors:  Ju-Hwa Kim; Minji Chae; Won Ki Kim; You-Jin Kim; Han Sung Kang; Hyung Sik Kim; Sungpil Yoon
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3).

Authors:  Fuat Kaplan; Fulya Teksen
Journal:  Tumour Biol       Date:  2015-10-18

4.  Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest.

Authors:  Won Ki Kim; Ju-Hwa Kim; Kyungsil Yoon; Sunshin Kim; Jungsil Ro; Han Sung Kang; Sungpil Yoon
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

5.  Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.

Authors:  Maximilian Boesch; Alain G Zeimet; Holger Rumpold; Guenther Gastl; Sieghart Sopper; Dominik Wolf
Journal:  Stem Cells Transl Med       Date:  2015-07-01       Impact factor: 6.940

Review 6.  Cancer stem cells and chemoresistance: The smartest survives the raid.

Authors:  Jihe Zhao
Journal:  Pharmacol Ther       Date:  2016-02-17       Impact factor: 12.310

Review 7.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

Review 8.  Therapeutic strategies targeting cancer stem cells.

Authors:  Xiaoyan Ning; Jianchang Shu; Yiqi Du; Qiwen Ben; Zhaoshen Li
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

9.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

10.  Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.

Authors:  Ivana Gojo; Ming Tan; Hong-Bin Fang; Mariola Sadowska; Rena Lapidus; Maria R Baer; France Carrier; Jan H Beumer; Bean N Anyang; Rakesh K Srivastava; Igor Espinoza-Delgado; Douglas D Ross
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.